ALYSSA FELVER: Open Payments
NPI 1336765437 · LEE, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,589 in 64 payments from 25 companies in 2025. Trend: 2023 $1,662 · 2024 $1,433 · 2025 $1,589
Food & beverage: $1,589
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $228 |
| Lilly USA, LLC | 6 | $197 |
| Lundbeck LLC | 10 | $136 |
| ABIOMED | 1 | $104 |
| AstraZeneca Pharmaceuticals LP | 5 | $100 |
| Calliditas Therapeutics US Inc. | 1 | $99 |
| ABBVIE INC. | 4 | $92 |
| Novo Nordisk Inc | 4 | $85 |
| Sumitomo Pharma America, Inc. | 3 | $82 |
| Indivior Inc. | 4 | $75 |
Products named: REPATHA, REXULTI, ZEPBOUND, TARPEYO, GEMTESA, SUBLOCADE, KISUNLA, EVENITY.
Industry payments across MA — which companies pay providers there.
